Leonardo Mendoza, MD
Internal Medicine · Tucson, AZNPI 1194798496
Payments from drug & device makers
Across 55 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$113
- AbbVie$110
- Sumitomo Pharma America, Inc.$82
- Lilly USA, LLC$74
- Smith+Nephew$73
- AstraZeneca$63
- plus $469 from 20 others
What the payments were for
- Food & beverage$88390%
- Education$10010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $113 |
| AbbVie(2 entities) | 5 | $110 |
| Sumitomo Pharma America, Inc. | 6 | $82 |
| Lilly USA, LLC | 5 | $74 |
| Smith+Nephew | 5 | $73 |
| AstraZeneca | 4 | $63 |
| Almatica Pharma LLC | 3 | $49 |
| Lundbeck LLC | 2 | $36 |
| GSK | 2 | $34 |
| Bayer | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Novartis | 2 | $28 |
| Johnson & Johnson | 2 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $22 |
| Krystal Biotech Inc | 1 | $22 |
| Abbott | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Pfizer | 1 | $18 |
| Amgen | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Averitas Pharma Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$983 in reported general payments places this provider in the 75th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 167 | $141,047 |
| ZenpepLipase/Protease/Amylase | 11 | $66,938 |
| MounjaroTirzepatide | 51 | $57,215 |
| XareltoRivaroxaban | 79 | $55,625 |
| CreonLipase/Protease/Amylase | 21 | $46,223 |
| FarxigaDapagliflozin Propanediol | 50 | $40,535 |
| JanuviaSitagliptin Phosphate | 58 | $40,488 |
| EntrestoSacubitril/Valsartan | 49 | $34,805 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $34,669 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $28,828 |
| MyrbetriqMirabegron | 44 | $25,348 |
| GemtesaVibegron | 17 | $18,376 |
| JardianceEmpagliflozin | 17 | $14,738 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $12,379 |
| Restasis MultidoseCyclosporine | 16 | $11,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $18 | $141,047167 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $63 | $79,146104 claims |
| AbbVieCreon, Restasis Multidose, Synthroid | $110 | $61,07198 claims |
| Lilly USA, LLCMounjaro | $74 | $57,21551 claims |
| Johnson & JohnsonXarelto | $25 | $55,62579 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $34 | $42,12056 claims |
| NovartisEntresto | $28 | $34,80549 claims |
| Astellas Pharma US IncMyrbetriq | $113 | $25,34844 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $82 | $18,37617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Tucson
- Robert MutterperlTucson$5.3M
- Nebojsa SkrepnikTucson$4.7M
- Franz RischardTucson$3.7M
- Girish KaramchandaniTucson$2.9M
- Siddharth SinghalTucson$1.3M
- Rajesh JanardhananTucson$983K
- Carl DienerTucson$750K
- Roxana RodriguezTucson$547K
- Mona SelejTucson$440K
- Muhammad HusnainTucson$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.